NCT01603043View on ClinicalTrials.gov

A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Geographic Atrophy
Interventions
DRUG

Al-78898A

0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection

DRUG

Sham injection

Mock injection administered as an empty hub without needle

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY